Advanced Diabetic Nephropathy with Nephrotic Range Proteinuria: A Pilot Study of the Long-Term Efficacy of Subcutaneous ACTH Gel on Proteinuria, Progression of CKD, and Urinary Levels of VEGF and MCP-1
Figure 4
(a) The change in serum creatinine for patients randomized to the 16-unit dose from baseline to 12 months of completion of ACTH therapy. There was no significant change in average serum Cr. A single patient from this group developed ESRD within 17 months. (b) The change in serum creatinine for patients randomized to the 32-unit dose from baseline to 12 months of completion of ACTH therapy. There was a trend toward increased Cr at 12 months, but this difference did not reach statistical significance. Three of six patients in this group developed ESRD within 14.3 months. (c) The change in serum creatinine for age-matched diabetic controls not receiving ACTH therapy. Serum Cr significantly increased () over 18 months. Of the 23 patients, 12 reached ESRD within 18 months.
